MeSH D002836 - hemophilia b
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Pfizer | Coagulation factor ix recombinant human | BeneFIX |  | 1997-08-27 |  |  |
| Orphan Medical | Eftrenonacog alfa | Alprolix |  | 2016-05-12 |  |  |
| Novo Nordisk | Coagulation factor viia recombinant human | NovoSeven |  | 1996-02-23 |  |  |
| Nonacog beta pegol | Refixia |  | 2017-06-02 |  |  | |
| Sanquin | Coagulation factor ix human | Nonafact |  | 2001-07-03 |  |  |
| Laboratoire Francais du Fractionnement et des Biotechnologies S.A. | Coagulation factor viia recombinant human | Cevenfacta |  | 2022-07-15 |  |  |
| Baxalta | Coagulation factor ix recombinant human | Rixubis |  | 2014-12-19 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
83%10/12
Phase 2
69%9/13
Phase 3
54%14/26
Approved: 5Overall Success rate: 31%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use